Active Ingredient History
NAMENDA (marketed under the brands Namenda among others) is an N-methyl-D-aspartate (NMDA) receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. Persistent activation of central nervous system N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer’s disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. There is no evidence that memantine prevents or slows neurodegeneration in patients with Alzheimer’s disease. Memantine showed low to negligible affinity for GABA, benzodiazepine, dopamine, adrenergic, histamine and glycine receptors and for voltage-dependent Ca2+, Na+ or K+ channels. Memantine also showed antagonistic effects at the 5HT3 receptor with a potency similar to that for the NMDA receptor and blocked nicotinic acetylcholine receptors with one-sixth to one-tenth the potency. In vitro studies have shown that memantine does not affect the reversible inhibition of acetylcholinesterase by donepezil, galantamine, or tacrine. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Alzheimer Disease (approved 2003)
Acute Febrile Encephalopathy (Phase 4)
Affect (Phase 4)
AIDS Dementia Complex (Phase 2)
Alcohol Drinking (Phase 3)
Alcohol-Induced Disorders (Phase 2)
Alcoholism (Phase 4)
Alzheimer Disease (Phase 4)
Amphetamine-Related Disorders (Phase 2/Phase 3)
Amyotrophic Lateral Sclerosis (Phase 2/Phase 3)
Anemia, Sickle Cell (Phase 2)
Anxiety Disorders (Phase 3)
Aphasia (Phase 4)
Asperger Syndrome (Phase 2)
Autism Spectrum Disorder (Phase 4)
Autistic Disorder (Phase 3)
Binge-Eating Disorder (Phase 4)
Bipolar Disorder (Phase 4)
Brain Diseases (Phase 2)
Brain Injuries, Traumatic (Phase 4)
Brain Neoplasms (Phase 3)
Breast Neoplasms (Phase 3)
Cancer Pain (Phase 2/Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Renal Cell (Phase 3)
Central Nervous System Diseases (Phase 1)
Central Nervous System Neoplasms (Early Phase 1)
Central Nervous System Stimulants (Phase 2)
Cocaine-Related Disorders (Phase 2)
Cognition Disorders (Phase 3)
Cognitive Dysfunction (Phase 3)
Colorectal Neoplasms (Phase 2)
Complex Regional Pain Syndromes (Phase 4)
Compulsive Behavior (Phase 2)
Craniopharyngioma (Phase 2)
Delirium (Phase 4)
Dementia (Phase 4)
Dementia, Vascular (Phase 3)
Depression (Phase 4)
Depressive Disorder (Phase 4)
Depressive Disorder, Major (Phase 2/Phase 3)
Dermatology (Phase 2)
Disability Evaluation (Phase 3)
Down Syndrome (Phase 4)
Drug Therapy (Phase 2/Phase 3)
Ependymoma (Phase 2)
Epilepsy (Phase 1)
Essential Tremor (Phase 4)
Fibromyalgia (Phase 3)
Frontotemporal Dementia (Phase 4)
Frontotemporal Lobar Degeneration (Phase 4)
Gait Disorders, Neurologic (Phase 4)
Gambling (Phase 2)
General Surgery (Phase 4)
Glaucoma, Open-Angle (Phase 3)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 1)
Growth and Development (Phase 2)
Healthy Volunteers (Phase 4)
Hematoma, Subdural, Chronic (Early Phase 1)
Heroin Dependence (Phase 2/Phase 3)
HIV Infections (Phase 2)
Huntington Disease (Phase 4)
Intellectual Disability (Phase 2)
Ischemic Stroke (Phase 3)
Lewy Body Disease (Phase 4)
Lung Neoplasms (Phase 3)
Lupus Erythematosus, Systemic (Phase 2)
Melanoma (Phase 3)
Memantine (Phase 3)
Memory Disorders (Phase 4)
Migraine Disorders (Phase 3)
Multiple Sclerosis (Phase 4)
Muscle Weakness (Phase 1)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 3)
Neoplasms, Germ Cell and Embryonal (Phase 2)
Neuralgia (Phase 3)
Nystagmus, Pathologic (Phase 4)
Obesity (Phase 1)
Obsessive-Compulsive Disorder (Phase 3)
Opioid-Related Disorders (Phase 2/Phase 3)
Orthostatic Intolerance (Phase 2)
Pain (Phase 4)
Pain, Postoperative (Phase 4)
Parkinson Disease (Phase 4)
Pharmacokinetics (Phase 1)
Physiological Effects of Drugs (Phase 4)
Prostatic Neoplasms (Phase 2)
Psychophysiologic Disorders (Phase 3)
Psychotic Disorders (Phase 4)
Schizophrenia (Phase 4)
Signs and Symptoms (Phase 1)
Small Cell Lung Carcinoma (Phase 3)
Stomach Diseases (Phase 1)
Stress Disorders, Post-Traumatic (Phase 4)
Stroke (Phase 4)
Substance-Related Disorders (Phase 3)
Tachycardia (Phase 1/Phase 2)
Tension-Type Headache (Phase 3)
Tobacco Use Disorder (Phase 2)
Trichotillomania (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
